|
Takeda’s Takhzyro last week won expanded
use as a prophylaxis to prevent
attacks of hereditary angioedema (HAE) in pediatric patients age 2 to 12. The
injectable was previously approved in patients 12 and older. For that
indication, Takhzyro holds covered or better status for 95% of all insured
lives under the medical benefit. It is covered for just 15% of insured lives
under the pharmacy benefit. |
|
SOURCE: MMIT Analytics,
as of 2/8/23 |
No comments:
Post a Comment